What Is a Working Cell Bank in Biomanufacturing?

A working cell bank is a carefully prepared and frozen collection of cells, drawn from a single well-characterized parent stock, that serves as the day-to-day starting material for manufacturing biological products like vaccines, monoclonal antibodies, and cell therapies. It sits one step below a master cell bank in a two-tier system designed to protect the original cell line from contamination, genetic drift, and simple exhaustion. The concept sounds straightforward, but the practical details of freezing living cells, confirming they are what they claim to be, and keeping them viable across years of storage involve a surprising amount of science and logistics.

The Two-Tier Banking System

Nearly all biopharmaceutical manufacturing relies on a tiered cell-banking hierarchy. At the top sits the master cell bank, a large batch of vials frozen from a single, thoroughly tested cell population. Below it sits the working cell bank, which is made by thawing one or a few vials from the master bank, expanding those cells through a limited number of growth cycles, and then freezing them into a new set of vials. Production runs draw from working cell bank vials, never directly from the master bank.

The logic is risk management. The master bank is the irreplaceable original. If production staff thawed a master-bank vial every time they needed to start a manufacturing run, the master bank would eventually run out, and each thaw event would be one more chance for something to go wrong, whether contamination, a labeling mix-up, or a freezer accident. By interposing the working cell bank, manufacturers protect the master while still having a standardized, well-characterized starting point for every batch. When the working cell bank runs low, another one is generated from a fresh master-bank vial, keeping the chain going for years or even decades. Clinical-grade iPSC lines, for example, follow exactly this structure: master and working cell banks are produced under strict cleanroom conditions to support downstream therapeutic use.¹

Each tier has a defined passage number, meaning the number of times the cells have been grown and split since the original isolation. Keeping passage numbers low matters because cells can accumulate mutations or shift their behavior over many rounds of division. The working cell bank typically sits only a few passages beyond the master bank, ensuring the cells used in production are still genetically and functionally close to the original.

How the Cells Are Frozen

Living cells are mostly water, and water forms ice crystals when it freezes. Those crystals can puncture cell membranes and kill the cell outright. Even if ice stays outside the cell, the concentration of salts and other dissolved molecules in the remaining liquid rises sharply as water freezes out, creating osmotic stress that damages cells from the outside in.² Cryopreservation protocols are designed to navigate between these two threats.

The standard approach is controlled-rate cooling: cells are chilled at a carefully managed pace, typically around one degree Celsius per minute, so that ice forms mainly outside the cell while the cell slowly dehydrates. Compounds called cryoprotectants are added before freezing to buffer against the rising solute concentrations. These protective chemicals reduce osmotic damage enough to let most cells survive the trip down to storage temperature.³ Both the cooling rate and the thawing rate matter: too slow on the way back up gives ice crystals time to recrystallize and grow, while too fast on the way down traps ice inside the cell.

The most widely used cryoprotectant is dimethyl sulfoxide, commonly known as DMSO. It penetrates cell membranes and prevents lethal ice formation inside the cell. Glycerol, ethylene glycol, and propylene glycol are also used, though the best choice depends on the cell type.⁴ Once cells reach roughly −80 °C or colder, metabolic activity effectively stops and the cells enter a kind of suspended animation.

How Long Frozen Cells Remain Viable

One common worry is that cells degrade over years of storage. The evidence is reassuring. A study of cardiac valve cells stored in liquid nitrogen for up to 13 years found no significant loss of viability beyond what occurred during the initial freezing and thawing process itself. Cells grew normally from the stored tissue, maintained their structure, and showed almost no signs of irreversible damage regardless of how long they had been banked.⁵

Even storage at −80 °C, which is warmer than liquid nitrogen’s −196 °C, can preserve cells for years. Researchers who kept human and bovine cells at −80 °C for eight years found that viability stayed above 90 percent, matching cells stored in liquid nitrogen over the same period. The cells looked the same under a microscope, grew at the same rate, secreted the same proteins, and showed identical genetic fingerprints.⁶ That last point is worth underscoring: genetic identity remained stable across nearly a decade of frozen storage, a finding that matters enormously for anyone relying on a working cell bank to produce a consistent product batch after batch.

The practical implication is that a well-prepared working cell bank does not have an expiration date in the usual sense. As long as the freezer stays cold and the vials remain sealed, the cells inside should be just as useful years later as they were the week they were banked. Stability testing, where manufacturers periodically thaw a vial and check viability and function, confirms this over the life of the bank.

Quality Control Testing

A vial of frozen cells is only useful if you know exactly what is inside it and can prove nothing unwanted hitched a ride. The qualification of any cell bank involves testing for cell identity and for microbial contaminants including bacteria, fungi, mycoplasmas, and viruses.⁷ Each category of testing addresses a distinct risk.

Identity testing confirms the cells are actually the cell line they are supposed to be. This is less trivial than it sounds. Cross-contamination between cell lines is a well-documented problem in laboratories worldwide. A study of 100 human cell lines at one national repository found that close to one in five were cross-contaminated, meaning the cells in the vial were not the cells the label claimed.⁸ The standard tool for catching this is short tandem repeat profiling, which produces a genetic fingerprint unique to each cell line. This kind of DNA-based authentication is now considered a minimum quality standard for any biobank.⁹

Mycoplasma testing is equally critical. Mycoplasmas are tiny bacteria that lack a cell wall, making them invisible under a standard microscope and resistant to many common antibiotics. They can silently infect a cell culture, altering gene expression, growth rates, and experimental results without anyone noticing. Real-time PCR-based detection methods have become the preferred approach because they are fast and sensitive.

Virus testing rounds out the safety profile. Vaccines and biologics manufactured from cell substrates must be screened for adventitious viruses, meaning viruses that are not supposed to be there. Both older methods using cell-culture-based detection and newer molecular approaches are used, though the sensitivity and breadth of these assays vary. A systematic evaluation of routine adventitious virus assays tested 16 different viruses and found that different methods caught different viruses, with no single test detecting them all.¹⁰ This is why regulators require a panel of complementary tests rather than relying on any single assay.

Why Working Cell Banks Exist Instead of Just Freezing More Master Vials

An obvious question: why not skip the working cell bank and just make a very large master bank? In principle you could, but it introduces problems. Creating a master cell bank is expensive and time-consuming because of the exhaustive testing required. Every vial in the master bank must be accounted for under strict chain-of-custody documentation. The more often you dip into it, the greater the cumulative risk of contamination events, mislabeling, or accidental temperature excursions during handling.

The working cell bank acts as a buffer. It absorbs the routine wear and tear of manufacturing while the master bank sits undisturbed in deep storage. If something goes wrong with a working cell bank, whether contamination, a freezer failure, or unexpected cell behavior, the master bank is unaffected. You simply generate a new working cell bank from a fresh master-bank vial. This separation of concerns is a core principle of pharmaceutical manufacturing, and it applies equally to traditional biologics like monoclonal antibodies and newer products like iPSC-derived cell therapies.

Scaling Up From a Single Vial

A working cell bank vial typically contains a few million cells suspended in a small volume of cryoprotectant solution. Getting from that modest starting point to a production-scale bioreactor holding thousands of liters involves several expansion steps: the cells are thawed, placed in a small culture vessel, allowed to grow and divide, then transferred to progressively larger vessels until the culture volume is large enough to seed the production bioreactor.

This expansion train can take a week or more and involves multiple manual transfers between different-sized flasks, each one a potential point of contamination or operator error. One strategy to shorten this process is high-density cell banking, where working cell bank vials are prepared at much higher cell concentrations than usual. Research has demonstrated that high-density cell banks can eliminate several intermediate shake-flask steps, saving up to nine days of operation during scale-up and allowing direct seeding into larger bioreactor systems.¹¹ For a manufacturing facility running multiple products, shaving nine days off each campaign translates directly into more batches per year and lower per-dose costs.

Keeping Cells Cold During Transport

Working cell bank vials do not always stay in the freezer where they were made. They may need to travel to a contract manufacturing site on a different continent, or from a central repository to a hospital for a cell therapy. Maintaining ultra-cold temperatures during transit is a serious logistical challenge.

The standard solution is a dry shipper, a specialized container that absorbs liquid nitrogen into a porous material so the interior stays extremely cold without the hazard of free-flowing cryogenic liquid. Real-world temperature data from cell therapy shipments show that dry shippers maintain payload temperatures well below the critical −150 °C threshold, with mean payload temperatures around −191 °C during vendor transit and around −173 °C during shorter institutional transport to the patient bedside. Importantly, external ambient temperatures had no measurable correlation with internal payload temperature, meaning the shippers held up whether it was winter or summer outside.¹²

Even with reliable equipment, things occasionally go wrong. A recent case report described a catastrophic liquid nitrogen storage failure at a hospital. The recovery effort involved rapidly transferring roughly 40 units of banked cells per trip using dry shippers to an off-site storage facility. The operation was completed without losing product integrity, and clinical operations continued uninterrupted.¹³ That kind of contingency planning, having backup storage identified and dry shippers on hand, is part of what it means to maintain a cell bank responsibly.

The Regulatory Landscape

Cell banks used in pharmaceutical manufacturing are governed by guidelines from agencies like the FDA, EMA, and the International Council for Harmonisation (ICH). These guidelines specify what tests must be performed, how much documentation is required, and how the cell bank’s chain of custody must be maintained. The rules were originally written for traditional biologics, but the rise of cell therapies, particularly those based on iPSCs, is pushing regulators to update their frameworks.

Current ICH guidelines cover biotechnological products broadly, but manufacturers of iPSC cell banks for clinical use have found that the existing rules do not perfectly fit their products. Areas under active discussion include which methods should be permitted for generating iPSCs, what minimum identity and purity testing should look like for these newer cell types, and how stability testing should be conducted over time.¹⁴ The gap between existing guidelines and the reality of advanced therapies is one of the more active areas of regulatory science right now.

Moving Beyond DMSO

DMSO has been the default cryoprotectant for decades, but it is not without problems. When patients receive infusions of cell therapy products that still contain residual DMSO, side effects can include cardiovascular symptoms, nausea, neurological reactions, and allergic responses. Beyond patient safety, DMSO can alter the surface markers and function of immune cells like T cells and NK cells, which is a real concern when those cells are the therapeutic product. Manufacturing scale-up with DMSO-based formulations also introduces challenges for both autologous and allogeneic cell therapies.¹⁵

Researchers have been evaluating alternatives including various sugars, proteins, polymers, and amino acids. A recent head-to-head comparison tested a DMSO-free cryoprotectant against a standard DMSO-based solution for banking mesenchymal stem cells across all three stages of the manufacturing process: master cell bank, working cell bank, and final product. The DMSO-free formulation outperformed the conventional solution on pre-freeze stability, post-thaw recovery, expansion potential, and functional performance, while maintaining cell identity and genomic stability.¹⁶ Results like these suggest the field is approaching a point where DMSO-free banking could become practical for clinical-grade manufacturing, though widespread adoption will require regulatory acceptance and more validation across different cell types.

Bacterial and Non-Mammalian Cell Banks

Most of the discussion around working cell banks focuses on mammalian cells, but bacteria and yeast also get banked for production of recombinant proteins, enzymes, and some vaccines. The principles are similar: a master bank is made, working banks are derived from it, and both are stored frozen. The cryopreservation details differ, though. Bacterial cells are typically frozen in glycerol rather than DMSO. Studies of E. coli populations archived by freezing found that the optimal glycerol concentration varied by strain, ranging from about 15 percent to as high as 20–25 percent, and that fewer than 40 percent of cells survived a freeze-thaw cycle even under optimized conditions.¹⁷

That survival rate sounds alarming compared to the 90-plus percent viability seen with well-prepared mammalian cell banks, but bacteria reproduce so quickly that the survivors rapidly repopulate a culture. The more interesting concern from that research is genetic: a freeze-thaw cycle that kills off a large fraction of the population acts as a bottleneck, potentially reducing the genetic diversity of the surviving culture. For most manufacturing purposes, where you want a genetically uniform population producing a single product, this bottleneck is actually a feature rather than a bug. But for researchers using frozen stocks to study bacterial evolution or diversity, it is a genuine confound worth keeping in mind.

When a Working Cell Bank Needs to Be Replaced

A working cell bank is a finite resource. Every production campaign consumes one or more vials, and eventually the bank is depleted. When that happens, a new working cell bank is generated from the master bank. This sounds simple, but it triggers a cascade of quality requirements. The new bank must pass all the same identity, sterility, and adventitious agent testing as the original. Manufacturers also typically perform comparability testing: confirming that the product made from the new working cell bank matches the product made from the old one in terms of potency, purity, and other critical quality attributes.

The same issue arises in a more dramatic form when a master cell bank itself starts running low. Generating a new master bank from the original cell line (if it is still available) or from a surviving master-bank vial is possible, but the testing and regulatory requirements are far more extensive. Any change at the master-bank level can potentially affect every downstream product, so regulators expect thorough documentation showing the new bank is functionally equivalent to the old one. For products already approved and on the market, a master bank change may require formal notification to or approval from regulatory agencies.

This lifecycle management, the ongoing cycle of banking, depleting, rebanking, and demonstrating equivalence, is one of the less glamorous but most consequential aspects of biological manufacturing. A well-planned banking strategy at the outset, making enough master-bank vials to last the expected commercial life of the product, can save years of requalification work down the line. Companies that underestimate how many vials they will need sometimes find themselves in the uncomfortable position of running out of master bank before their product has finished its commercial run, a situation that is expensive and time-consuming to resolve.